15 Jul
Real-world effectiveness of cenobamate in drug-resistant and ultra-refractory epilepsy: A multicenter study
Objective: To evaluate the real-world effectiveness, safety, and treatment retention of cenobamate (CNB) in patients with drug-resistant epilepsy (DRE), including ultra-refractory epilepsy (URE), high seizure burden, and extensive prior treatment history.
Methods: We conducted a retrospective, multicenter study of 500 adults with DRE (focal or combined epilepsy) who were treated with CNB at three Czech tertiary epilepsy centers. Among these patients, 83.4% met criteria for URE. Seizure outcomes, treatment retention, and adverse events were analyzed, with stratification by treatment duration and cumulative ASM exposure (number of previous and concomitant anti-seizure medications). Primary outcomes were ≥ 50% responder rate and seizure freedom at 12 months.
Results: Among 436 patients with evaluable seizure data after ≥ 3 months of CNB treatment, 55.7% achieved ≥ 50% seizure reduction and 16.5% became seizure-free. At 12 months (n = 331), ≥ 50% response was achieved in 61.6%, and 18.1% became seizure-free.